$852 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 137 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | MERCK & CO INC | $23,915,000 | -12.1% | 425,000 | 0.0% | 2.81% | -27.7% | |
| SRPT | SAREPTA THERAPEUTICS INC | $21,421,000 | +22.7% | 384,997 | 0.0% | 2.51% | +0.9% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $15,962,000 | -12.6% | 450,000 | 0.0% | 1.87% | -28.2% | |
| PFE | PFIZER INC | $14,126,000 | +1.5% | 390,000 | 0.0% | 1.66% | -16.5% | |
| SHPG | SHIRE PLCsponsored adr | $13,418,000 | +1.3% | 86,500 | 0.0% | 1.57% | -16.7% | |
| CLVS | CLOVIS ONCOLOGY INC | $10,744,000 | -17.5% | 158,000 | 0.0% | 1.26% | -32.1% | |
| AGN | ALLERGAN PLC | $9,815,000 | -20.2% | 60,000 | 0.0% | 1.15% | -34.3% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $7,100,000 | -5.6% | 1,044,131 | 0.0% | 0.83% | -22.4% | |
| GOOGL | ALPHABET INCcap stk cl a | $6,075,000 | +8.2% | 5,767 | 0.0% | 0.71% | -11.0% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $5,187,000 | +10.5% | 129,474 | 0.0% | 0.61% | -9.1% | |
| ARRY | ARRAY BIOPHARMA INC | $5,184,000 | +4.1% | 405,000 | 0.0% | 0.61% | -14.5% | |
| STML | STEMLINE THERAPEUTICS INC | $4,680,000 | +40.5% | 300,000 | 0.0% | 0.55% | +15.6% | |
| KDMN | KADMON HLDGS INC | $3,982,000 | +8.1% | 1,100,000 | 0.0% | 0.47% | -11.2% | |
| EDGE | EDGE THERAPEUTICS INC | $3,127,000 | -12.7% | 333,737 | 0.0% | 0.37% | -28.2% | |
| CMTA | CLEMENTIA PHARMACEUTICALS IN | $3,094,000 | +12.4% | 163,000 | 0.0% | 0.36% | -7.6% | |
| BOLD | AUDENTES THERAPEUTICS INC | $2,969,000 | +11.6% | 95,000 | 0.0% | 0.35% | -8.4% | |
| CASC | CASCADIAN THERAPEUTICS INC | $2,520,000 | -9.5% | 681,210 | 0.0% | 0.30% | -25.4% | |
| SMMT | SUMMIT THERAPEUTICS PLCspons ads | $2,349,000 | -11.5% | 212,018 | 0.0% | 0.28% | -27.2% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $2,294,000 | -35.0% | 221,430 | 0.0% | 0.27% | -46.6% | |
| ARDX | ARDELYX INC | $2,277,000 | +17.9% | 345,000 | 0.0% | 0.27% | -3.3% | |
| SELB | SELECTA BIOSCIENCES INC | $2,242,000 | -46.2% | 228,534 | 0.0% | 0.26% | -55.8% | |
| CTIC | CTI BIOPHARMA CORP | $2,234,000 | -16.0% | 833,633 | 0.0% | 0.26% | -30.9% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $2,177,000 | -25.1% | 248,472 | 0.0% | 0.26% | -38.6% | |
| AAP | ADVANCE AUTO PARTS INCcall | $2,093,000 | +0.5% | 21,000 | 0.0% | 0.25% | -17.2% | |
| MA | MASTERCARD INCORPORATEDcl a | $1,744,000 | +7.2% | 11,525 | 0.0% | 0.20% | -11.6% | |
| PRQR | PROQR THRAPEUTICS N V | $1,709,000 | -33.5% | 530,000 | 0.0% | 0.20% | -45.2% | |
| ALRN | AILERON THERAPEUTICS INC | $1,318,000 | -21.2% | 125,000 | 0.0% | 0.16% | -35.1% | |
| SNA | SNAP ON INC | $1,271,000 | +16.9% | 7,292 | 0.0% | 0.15% | -3.9% | |
| AQXP | AQUINOX PHARMACEUTICALS INC | $888,000 | -17.2% | 75,535 | 0.0% | 0.10% | -32.0% | |
| UNH | UNITEDHEALTH GROUP INC | $441,000 | +12.5% | 2,000 | 0.0% | 0.05% | -7.1% | |
| TJX | TJX COS INC NEW | $443,000 | +3.5% | 5,800 | 0.0% | 0.05% | -14.8% | |
| SERV | SERVICEMASTER GLOBAL HLDGS I | $410,000 | +9.6% | 8,000 | 0.0% | 0.05% | -9.4% | |
| SAGE | SAGE THERAPEUTICS INCput | $395,000 | +163.3% | 2,400 | 0.0% | 0.05% | +119.0% | |
| WSO | WATSCO INC | $357,000 | +5.6% | 2,100 | 0.0% | 0.04% | -12.5% | |
| MHK | MOHAWK INDS INC | $303,000 | +11.4% | 1,100 | 0.0% | 0.04% | -7.7% | |
| ECL | ECOLAB INC | $268,000 | +4.3% | 2,000 | 0.0% | 0.03% | -16.2% | |
| LOW | LOWES COS INC | $242,000 | +16.3% | 2,600 | 0.0% | 0.03% | -6.7% | |
| SEE | SEALED AIR CORP NEW | $222,000 | +15.6% | 4,500 | 0.0% | 0.03% | -3.7% | |
| ULTI | ULTIMATE SOFTWARE GROUP INC | $175,000 | +15.1% | 800 | 0.0% | 0.02% | -4.5% | |
| LVNTA | LIBERTY INTERACTIVE CORP | $163,000 | -5.8% | 3,000 | 0.0% | 0.02% | -24.0% | |
| XRAY | DENTSPLY SIRONA INC | $165,000 | +10.0% | 2,500 | 0.0% | 0.02% | -9.5% | |
| TRIP | TRIPADVISOR INC | $138,000 | -14.8% | 4,000 | 0.0% | 0.02% | -30.4% | |
| CMG | CHIPOTLE MEXICAN GRILL INC | $116,000 | -5.7% | 400 | 0.0% | 0.01% | -22.2% | |
| VSTO | VISTA OUTDOOR INC | $87,000 | -37.0% | 6,000 | 0.0% | 0.01% | -50.0% | |
| ATHX | ATHERSYS INC | $1,000 | -50.0% | 773 | 0.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.